– Data to highlight the penetration of olutasidenib across the blood brain barrier and preliminary safety and clinical activity from an ongoing Phase 1b/2 study –
WATERTOWN, Mass.–(BUSINESS WIRE)–FORMA Therapeutics, Inc. announced today that abstracts for the company’s next generation IDH1m inhibitor, olutasidenib (FT-2102), have been accepted for two presentations at the 2019 Society for NeuroOncology Annual Meeting, taking place November 20-24, 2019 in Phoenix, Arizona. Olutasidenib was designed to have a differentiated efficacy, durability and safety profile, as well as blood brain barrier penetrance, and is intended to treat all cancers with IDH1 mutations, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), gliomas and other solid tumors.
“I am proud of the progress FORMA has made in the first eight months of 2019 and am truly excited for this next phase of growth for our company centered on our wholly-owned therapeutic pipeline focused on rare hematologic diseases and cancers,” said Frank Lee, CEO of FORMA Therapeutics. “Gliomas are the most common, aggressive and difficult-to-treat primary brain tumors, with current treatment options limited to surgery, chemotherapy and radiation. Furthermore, gliomas typically affect relatively young patients. We look forward to presenting data regarding the brain penetrant activity of olutasidenib as well as initial results from our ongoing Phase 1b/2 study in patients with relapsed/refractory IDH1 mutant gliomas this November at SNO.”
Olutasidenib Status in Gliomas/Solid Tumors:
- An ongoing Phase 1b/2 study of olutasidenib is enrolling patients with gliomas or other advanced solid tumors with an IDH1 mutation.
Data from olutasidenib clinical trials have been submitted for presentation at medical meetings in the fourth quarter of 2019. Abstracts accepted for presentation at SNO include:
Oral Presentation: FT-2102 – A Potent and Selective Brain Penetrant Inhibitor of Mutant Isocitrate Dehydrogenase
Date and Time: Wednesday, November 20, 2019, 9:45-9:55 AM, MST
Oral Abstract Session: BBB Physiology at the SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS
Presenter: Maria Ribadeneira, PhD, FORMA Therapeutics
E-Talk Presentation: Phase 1 study of FT-2102, an inhibitor of mutant IDH1, in patients with relapsed/refractory IDH1 mutant gliomas: preliminary safety and clinical activity
Date and Time: Saturday, November 23, 2019, 5:20 PM – 5:24 PM, MST
E-Talks Session: Group 1: Adult Therapeutics/Immunology Rare Tumors
Presenter: Macarena de la Fuente, MD, Sylvester Cancer Center, University of Miami
- Oral Presentation: FT-2102 – A Potent and Selective Brain Penetrant Inhibitor of Mutant Isocitrate Dehydrogenase
FORMA’s most advanced clinical asset, olutasidenib was designed as a potent and selective next generation inhibitor of mutated isocitrate dehydrogenase 1 (IDH1m) intended to treat patients with relapsed/refractory acute myeloid leukemia (RR/AML) or myelodysplastic syndrome (MDS), and patients with glioma and other solid tumors with an IDH1 mutation. IDH1 is a natural enzyme that is part of the normal metabolism of all cells, but when mutated its activity can promote blood malignancies and solid tumors. IDH1 mutations are present in up to 16% of patients with AML and over 80% of patients with low-grade gliomas. In AML, hypermethylation driven by IDH mutations inhibits normal differentiation of progenitor cells leading to accumulation of immature blasts. Quality of life declines with each successive line of treatment for AML and well-tolerated treatments in relapsed disease remain an unmet need. In gliomas, IDH1 mutations occur early in the tumor pathogenesis and persist throughout progression from a neural stem or progenitor cell. Gliomas are the most common, aggressive and difficult-to-treat primary brain tumors and high-grade gliomas are associated with poor long-term prognosis, with a median survival ranging from 5 to 7 years. Treatment options for relapsed glioma are limited. The rationale for targeting IDH1m is to reverse the oncogenic hypermethylated state to reduce tumor burden through induction of differentiation of immature blasts in AML and by slowing or stopping cancer cell growth in glioma.
In addition to the ongoing Phase 1b/2 study in patients with gliomas and other advanced solid tumors with an IDH1 mutation, a multi-cohort study with olutasidenib as a single agent and in combination with azacitidine is currently enrolling patients with AML and MDS, including a pivotal arm with olutasidenib as a single agent in R/R AML. Patients with treatment-naïve AML and R/R MDS with IDH1m are also being evaluated. Top-line data in patients with R/R AML are expected in the first half of 2020. If there is a positive outcome in R/R AML patients, a new drug application (NDA) is expected to be filed in the second half of 2020.
FORMA Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines that will make a difference for patients in need. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic, and metabolic indications. For more information, please visit the company website at www.formatherapeutics.com.
Kari Watson, +1 781-235-3060
Stephanie Ascher +1 212-362-1200
Stern Investor Relations
Subscribe to PICANTE via Email
Follow us on Facebook
Subaru Chooses TomTom Navigation for All-New US Vehicles
Continuity Wraps Up a Strong 2019 with a Strategic Acquisition, the Launch of a New Product and Multiple New Client Signings
ZetaDisplay adapts its organization to increase scalability and growth
GridGain’s Strong Market Momentum Continued in 2019
Microchip Joins Responsible Business Alliance (RBA) – the Global Industry Coalition Dedicated to Corporate Social Responsibility
CDK Global to Announce Second Quarter Fiscal 2020 Financial Results on February 4, 2020
Phenom People Raises $30 Million in Series C Proving the HR Shift Towards AI-Powered Talent Experiences
NETSOL Technologies to Ring Nasdaq Closing Bell on Tuesday, January 21, 2020
Vouch uses Socotra’s cloud-based platform to launch insurance products tailored for high-growth startups
Timeout called on online negativity as mobile users are invited to #TextForHumanity
Design Intelligence Award 2020 Is Looking for the Most Outstanding Design
CORRECTING and REPLACING Robins Kaplan Announces Bremer Bank Employee-Shareholders File Class-Action Lawsuit Against Three Trustees of Otto Bremer Trust
Shareholder Alert: Robbins LLP Announces Mohawk Industries, Inc. (MHK) Sued for Misleading Shareholders
Join TOPs of gambling hangout: BET2020 proposes a unique offer!
Digital Securities Guru Thomas Carter on The Two Keys That Will Unlock Mass Adoption of Cryptocurrency/Blockchain in 2020
Rovio Entertainment Corporation: Repurchase of own shares on 9 January 2020
What Does Public Domain Day Mean for Book Readers?
Rovio Entertainment Corporation: Repurchase of own shares on 10 January 2020
ZEDRA to acquire BNP Paribas Singapore Trust Corporation Limited
Buying a Home – What Should You Look After?
Follow our Tweets
Cannabis2 days ago
7 Things to Consider Before Buying Safe CBD Products
Augmented Reality (AR)4 days ago
Fluper Featured as the Best Android App Development Company By Crowd. Review
IT6 days ago
Jumei Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company at $20.0 per ADS
Guest Articles3 days ago
Robo.cash doubles funding volumes in 2019
Business and Management5 days ago
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of The RealReal, Inc. Investors (REAL)
IT5 days ago
MoneyGram and EbixCash Sign Exclusive Strategic Agreement to Expand Presence in India
Business and Management6 days ago
AWM Smart Shelf® Announces Partnership with OptiCrib Providing Technology for State-of-the Art Storeroom Management
Guest Articles3 days ago
Which Type of Furniture you should have for Elegant Look of Your Bedroom